Authors Dirat B, Ader I, Golzio M, Massa F, Mettouchi A, Laurent K, Larbret F, Malavaud B, Cormont M, Lemichez E, Cuvillier O, Tanti JF, Bost F
Molecular cancer therapeutics Feb 2015
Forkhead box O3 (FOXO3) transcription factor mediates apoptosis in BCG-infected macrophages.Authors Haoues M, Refai A, Mallavialle A, Barbouche MR, Laabidi N, Deckert M, Essafi M
Cellular microbiology Sep 2014
Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays.Authors Pharaon M, Tichet M, Lebrun-Frénay C, Tartare-Deckert S, Passeron T
JAMA dermatology Jun 2014
LIF mediates proinvasive activation of stromal fibroblasts in cancer.Authors Albrengues J, Bourget I, Pons C, Butet V, Hofman P, Tartare-Deckert S, Feral CC, Meneguzzi G, Gaggioli C
Cell reports Jun 2014
SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells.Authors Ohanna M, Bonet C, Bille K, Allegra M, Davidson I, Bahadoran P, Lacour JP, Ballotti R, Bertolotto C
Oncotarget Apr 2014
Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.Authors Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S, Bille K, Bahadoran P, Giacchero D, Lacour JP, Boyle GM, Hayward NF, Bertolotto C, Ballotti R
Oncotarget Dec 2013
Technical advance: actin CytoFRET, a novel FRET flow cytometry method for detection of actin dynamics in resting and activated T cell.Authors Larbret F, Dubois N, Brau F, Guillemot E, Mahiddine K, Tartare-Deckert S, Verhasselt V, Deckert M
Journal of leukocyte biology Sep 2013
Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.Authors Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S
Molecular cancer therapeutics Jun 2013
Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.Authors Robert G, Jullian V, Jacquel A, Ginet C, Dufies M, Torino S, Pottier A, Peyrade F, Tartare-Deckert S, Bourdy G, Deharo E, Auberger P
Oncotarget Dec 2012
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.Authors Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli Y, Cassuto JP, Raynaud S, Legros L, Pasquet JM, Mahon FX, Luciano F, Auberger P
Journal of molecular cell biology Aug 2012